# MIVI Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mivi-neuroscience

- Industry: Healthcare
- Headquarters: Eden Prairie, US
- Website: www.mivineuro.com
- Total disclosed funding: $35M
- Latest round: Series B (Jan 21, 2021)
- Investors on record: 4

## About

MIVI Neuroscience, Inc. specializes in developing innovative solutions for stroke treatment, focusing on advanced mechanical devices that enhance neurointerventional procedures and improve patient outcomes.Founded in 2013 and headquartered in Eden Prairie, US, MIVI Neuroscience, Inc. operates with a focus on stroke intervention technologies. The company raised USD 35.00 mn in Series B funding on January 21, 2021, with investors including Aphelion Capital, Concord Health Partners, Deerfield Management, and Perceptive Advisors. Founder Ben Constable has significant experience in the medical technology field, although details of prior ventures are not specified.MIVI Neuroscience specializes in innovative solutions for stroke treatment, primarily focusing on their flagship product, the DAISe™ Thrombectomy System. This advanced mechanical device is engineered to assist neurointerventional specialists in clot retrieval during stroke interventions, thereby minimizing distal embolization. The DAISe™ system addresses longstanding challenges in stroke management by enhancing the efficacy of clot removal procedures, ultimately aiming to improve patient outcomes in critical scenarios. MIVI collaborates closely with healthcare providers, specifically neurointerventional specialists, to tailor their offerings to the pressing needs of the medical community. The company’s products are primarily marketed within the United States, with a focus on hospitals and specialized stroke treatment facilities where advanced neurointervention techniques are employed.MIVI Neuroscience operates on a business model that focuses on direct sales to healthcare institutions and neurointerventional specialists, fostering relationships that enhance product adoption in clinical settings. The revenue structure is centered around the provision of their DAISe™ Thrombectomy System, which is positioned as a crucial tool in the treatment of ischemic strokes. Transactions typically involve direct sales agreements with hospitals and medical centers, where MIVI supplies the thrombectomy systems and possibly associated training and support services. Pricing plans for their products reflect the specialized nature of their offerings, catering to the unique needs of healthcare providers who require state-of-the-art technology for advanced stroke interventions. The company's revenue is thus generated from these direct sales engagements, ensuring that its products are accessible to the end-users who benefit most from their innovative solutions.In January 2021, MIVI Neuroscience, Inc. raised USD 35.00 mn in Series B funding, which will support the development of new products aimed at enhancing stroke intervention strategies. The company is exploring opportunities to expand its market presence beyond the United States, targeting regions with increasing demand for advanced stroke treatment technologies. Funding from the recent round will be allocated towards accelerating product development and facilitating entry into these new geographic markets.

## Funding rounds

- Series B, Jan 21, 2021, $35M — Aphelion Capital, Deerfield Management, Perceptive Advisors, Concord Health Partners

## Investors

- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Concord Health Partners (https://capitalatlas.ai/funds/concord-health-partners) — Series B